. home.aspx



Vertex Grows Gene Editing Presence, Acquiring Exonics and Expanding CRISPR Therapeutics Collaboration

June 10, 2019 / genengnews

Vertex Pharmaceuticals will carry out a potentially $2 billion expansion of its presence in gene editing through a pair of deals intended to enable the company to develop novel treatments for Duchenne Muscular Dystrophy (DMD) and Myotonic Dystrophy Type 1 (DM1). Vertex announced plans to acquire Exonics Therapeutics for approximately $1 billion, as well as spend an additional up-to $1.175 billion to expand a 3½-year-old, potentially $2.5 billion-plus collaboration with CRISPR Therapeutics that has resulted in the first clinical trial of a gene-editing therapy candidate sponsored by U.S. companies. “These transactions are highly aligned with our strategy of investing in scientific innovation to create transformative medicines for people with serious diseases,” Vertex chairman, president and CEO Jeffrey Leiden, MD, PhD, said in a statement. Based in Watertown, MA, Exonics uses its SingleCut CRISPR gene editing technology to develop treatments by repairing mutations tha...